Yahoo
LSE - Delayed Quote GBp

Ondine Biomedical Inc. (OBI.L)

9.75 0.00 (0.00%)
At close: October 30 at 4:35:20 PM GMT
Chart Range Bar
Loading chart for OBI.L
  • Previous Close 9.75
  • Open 9.62
  • Bid 9.50 x --
  • Ask 10.00 x --
  • Day's Range 9.50 - 9.75
  • 52 Week Range 0.10 - 15.50
  • Volume 195,218
  • Avg. Volume 488,220
  • Market Cap (intraday) 64.469M
  • Beta (5Y Monthly) 0.35
  • PE Ratio (TTM) --
  • EPS (TTM) -0.03
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 29.00

Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.

ondinebio.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

OBI.L
11.43%
FTSE 100 (^FTSE)
8.04%

1-Year Return

OBI.L
27.78%
FTSE 100 (^FTSE)
9.94%

3-Year Return

OBI.L
7.14%
FTSE 100 (^FTSE)
46.43%

5-Year Return

OBI.L
82.59%
FTSE 100 (^FTSE)
48.25%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY06
Revenue 536k
Earnings --
Profit Margin 0.00%

Q3

FY06

0
100K
200K
300K
400K
500K
0.0%

Analyst Insights

View More

Analyst Price Targets

29.00
29.00 Average
9.75 Current
29.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -236.33%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.88M

  • Net Income Avi to Common (ttm)

    -33.12M

  • Diluted EPS (ttm)

    -0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.32M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -14.96M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: